Axogen presents prostate nerve reconstruction market launch plans
AXGN•Axogen outlined plans to launch prostate nerve reconstruction using Avance nerve grafts, estimating a $754 million addressable market and an approximately $7,000 average selling price per procedure. Its presentation cited clinical experience across more than 220 patients and a survey in which 56% of hospital administrators supported adoption before broad insurance coverage.
1. Launch plans and market estimate
Axogen is moving forward with a prostate nerve reconstruction market launch using Avance nerve grafts. Its presentation estimated a $754 million total addressable market and a weighted average selling price of approximately $7,000 per procedure.
2. Clinical experience and adoption
Clinical experience included more than 220 reconstructed patients across 15 sites, with 117 patients having at least six months of follow-up. At six months, approximately 80% had better-than-expected erectile function and more than 95% had regained continence. A hospital administrator survey found 56% would support adoption before broad insurance coverage.
